Dr. Koh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
26520 Cactus Ave
Moreno Valley, CA 92555Phone+1 951-486-4000
Education & Training
- Cedars-Sinai Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1996
- Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1990 - 1993
- Saint Louis University School of MedicineClass of 1990
Certifications & Licensure
- CA State Medical License 1991 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
- Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab Start of enrollment: 2006 Mar 01
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 40 citationsMAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Can...Aparna Raj Parikh, Fa-Chyi Lee, Linda Yau, Han Koh, James A. Knost
Clinical Cancer Research. 2019-05-15 - 977 citationsMONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue
Journal of Clinical Oncology. 2017-06-03 - 540 citationsThe Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH ...George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue
JAMA Oncology. 2020-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: